International Business News - Salix http://www.ibtimes.com All articles are copyrighted by IBTimes.com 400 100 http://www.ibtimes.com/ http://www.ibtimes.com/images/top_logo_ibt2_3.gif Salix Pharmaceuticals Ltd. said Tuesday the drug rifaximin has received patent protection for a potential new use, treating irritable bowel syndrome. The U.S. Patent and Trademark Office issued a patent that will provide protection until August 2019, the company said in a statement. http://www.ibtimes.com/articles/20081118/salix-drug-receives-patent-for-potential-new-use.htm Tue, 18 Nov 2008 12:13:41 EST Salix Pharmaceuticals Ltd. said Monday its drug candidate rifaximin met its goals in a midstage clinical trial, improving quality of life for patients with irritable bowel syndrome. http://www.ibtimes.com/articles/20081006/salix-says-ibs-drug-candidate-met-goal-in-study.htm Mon, 06 Oct 2008 11:00:38 EDT Salix Pharmaceuticals Ltd. said Monday it filed a lawsuit against Novel Laboratories Inc. over its colonoscopy preparation tablet, OsmoPrep. Salix said the lawsuit is in response to Somerset, N.J.-based Novel's application with the Food and Drug Administration to market a generic version of OsmoPrep before the patent expires in 2013. Salix filed the lawsuit in U.S. District Court for the District of New Jersey. http://www.ibtimes.com/articles/20080909/salix-pharmaceuticals-sues-novel-over-patent.htm Tue, 09 Sep 2008 08:00:22 EDT Salix Pharmaceuticals Ltd. said Friday it closed its offering of $60 million in debt. The company, which makes pharmaceutical products to treat gastrointestinal disease, said the sale of the 5.5 percent convertible senior notes due 2028 included the exercise of the initial purchasers' $7.5 million over-allotment option. http://www.ibtimes.com/articles/20080822/salix-pharmaceuticals-closes-sale-of-60m-debt.htm Fri, 22 Aug 2008 11:59:49 EDT Salix Pharmaceuticals Ltd., a drug developer, said late Monday it priced an offering of $55 million in convertible senior notes due 2028. Salix, which focuses on gastrointestinal diseases, plans to use proceeds from the sale of the notes to acquire or license new drugs, develop and sell drug candidates and fund operations. http://www.ibtimes.com/articles/20080819/salix-pharma-offers-55-million-in-senior-notes.htm Tue, 19 Aug 2008 06:42:53 EDT Drug developer Salix Pharmaceuticals Ltd. said Monday it will issue $50 million in convertible senior notes to raise funds. The notes will be due in 2028. Salix said it may use the proceeds to acquire or license new drugs, develop and sell its drug candidates and fund its operations. http://www.ibtimes.com/articles/20080818/salix-to-offer-50-million-in-senior-notes.htm Mon, 18 Aug 2008 09:10:20 EDT